tetano
Editor, Senior Moderator
Antimicrob Agents Chemother. 2011 Jan 24. [Epub ahead of print]
Zanamivir, at 600 mg Twice Daily, Inhibits Oseltamivir-Resistant 2009 pandemic H1N1 Influenza Virus in an in vitro Hollow Fiber Infection Model System.
Brown AN, McSharry JJ, Weng Q, Adams JR, Kulawy R, Drusano GL.
Virology Therapeutics and Pharmacodynamics Laboratory, Center for Biodefense and Emerging Infections, Ordway Research Institute, Center for Medical Sciences, 150 New Scotland Avenue, Albany, New York 12208.
Abstract
In 2009, a novel H1N1 influenza A virus emerged that spread world wide initiating a pandemic. Various isolates obtained from disparate parts of the world were shown to be uniformly resistant to the adamantanes, but sensitive to neuraminidase inhibitors, oseltamivir and zanamivir. Over time, resistance to oseltamivir became more prevalent among pandemic H1N1 virus isolates while most of these H1N1 isolates remained susceptible to zanamivir. The government has proposed the use of intravenous (i.v.) zanamivir to treat serious influenza virus infections among hospitalized patients. To use zanamivir effectively in patients with severe influenza, it is necessary to know the optimal dose and schedule of administration of zanamivir that will inhibit the replication of oseltamivir-sensitive and resistant influenza viruses. Therefore, we performed studies using the in vitro hollow fiber infection model system to predict optimal dosing regimens for zanamivir against an oseltamivir- sensitive and an oseltamivir-resistant virus. Our results demonstrated that zanamivir, at a dose of 600 mg given Q12, inhibited the replication of oseltamivir-sensitive and oseltamivir-resistant influenza viruses throughout the course of the experiment. Thus, our findings suggest that intravenous zanamivir, at a dose of 600 mg Q12, could be used to treat hospitalized patients suffering from serious oseltamivir sensitive or resistant influenza virus infections.
PMID: 21263046 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21263046
Zanamivir, at 600 mg Twice Daily, Inhibits Oseltamivir-Resistant 2009 pandemic H1N1 Influenza Virus in an in vitro Hollow Fiber Infection Model System.
Brown AN, McSharry JJ, Weng Q, Adams JR, Kulawy R, Drusano GL.
Virology Therapeutics and Pharmacodynamics Laboratory, Center for Biodefense and Emerging Infections, Ordway Research Institute, Center for Medical Sciences, 150 New Scotland Avenue, Albany, New York 12208.
Abstract
In 2009, a novel H1N1 influenza A virus emerged that spread world wide initiating a pandemic. Various isolates obtained from disparate parts of the world were shown to be uniformly resistant to the adamantanes, but sensitive to neuraminidase inhibitors, oseltamivir and zanamivir. Over time, resistance to oseltamivir became more prevalent among pandemic H1N1 virus isolates while most of these H1N1 isolates remained susceptible to zanamivir. The government has proposed the use of intravenous (i.v.) zanamivir to treat serious influenza virus infections among hospitalized patients. To use zanamivir effectively in patients with severe influenza, it is necessary to know the optimal dose and schedule of administration of zanamivir that will inhibit the replication of oseltamivir-sensitive and resistant influenza viruses. Therefore, we performed studies using the in vitro hollow fiber infection model system to predict optimal dosing regimens for zanamivir against an oseltamivir- sensitive and an oseltamivir-resistant virus. Our results demonstrated that zanamivir, at a dose of 600 mg given Q12, inhibited the replication of oseltamivir-sensitive and oseltamivir-resistant influenza viruses throughout the course of the experiment. Thus, our findings suggest that intravenous zanamivir, at a dose of 600 mg Q12, could be used to treat hospitalized patients suffering from serious oseltamivir sensitive or resistant influenza virus infections.
PMID: 21263046 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21263046